Axim Cases and Covers in the News

Fri, 19 Jan 2018 03:06:55 GMT
This RSS feed URL is deprecatedThis RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Thu, 18 Jan 2018 05:16:23 GMT
Axim Biotechnologies (AXIM) Technicals Take Center Stage - Sheridan Daily

Axim Biotechnologies (AXIM) Technicals Take Center Stage
Sheridan Daily
Taking a further look at some technicals, shares of Axim Biotechnologies (AXIM) have a 200-day moving average of 8.51. The 50-day is 7.31, and the 7-day is sitting at 8.56. Using a wider time frame to assess the moving average such as the 200-day, may ...

and more »


Wed, 23 Nov 2016 16:11:44 GMT
Marijuana Stocks: Short AXIM Biotechnologies...If You Can Borrow And Finance The Shares - Seeking Alpha

Marijuana Stocks: Short AXIM Biotechnologies...If You Can Borrow And Finance The Shares
Seeking Alpha
AXIM has [1] a negative working capital position, [2] toxic convertibles, and [3] a negative gross profit on meager revenues. Fidelity indicates that AXIM shares are [1] “hard to borrow” and [2] charges a 6.5% annual interest rate to maintain a short ...



Tue, 27 Jun 2017 13:32:02 GMT
AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com - Marketwired (press release)

AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com
Marketwired (press release)
REDONDO BEACH, CA--(Marketwired - Jun 27, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. ( OTCQB ...

and more »


Tue, 21 Mar 2017 13:02:03 GMT
AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye ... - GlobeNewswire (press release)

AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye ...
GlobeNewswire (press release)
NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has retained the services of Ora®, Inc., a global Contract Research ...

and more »


Thu, 14 Sep 2017 08:04:11 GMT
Biosynthesis Technology Could Transform Cannabinoid Production - Markets Insider

Biosynthesis Technology Could Transform Cannabinoid Production
Markets Insider
... within the burgeoning sector, including Axim Biotechnologies, Inc. (OTC: AXIM), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) and pharmaceutical heavyweight Eli Lilly and Company (NYSE: LLY). Perhaps the clearest ...

and more »


Fri, 17 Mar 2017 14:38:29 GMT
Cannabinoid-based chewing gum enrolls patients in Ph II trial - In-PharmaTechnologist.com

In-PharmaTechnologist.com

Cannabinoid-based chewing gum enrolls patients in Ph II trial
In-PharmaTechnologist.com
“Cannabinoids and in particular CBD are well known to positively affect all of the above functions and therefore, are natural choices for the treatment in these cases​.” Forty patients were recruited based on Rome III criteria. The patients range in ...

and more »


Fri, 01 Dec 2017 04:28:53 GMT
GridIron BioNutrients (MYYZ) Bioceutical Breakthrough May Hold the Key to the NFL's Deadly CTE Crisis - MMJ Observer

GridIron BioNutrients (MYYZ) Bioceutical Breakthrough May Hold the Key to the NFL's Deadly CTE Crisis
MMJ Observer
You've seen it in the news – the NFL is facing a revenue-crushing epidemic. CTE–the devastating brain disease stalking the NFL has sent dozens of companies scrambling for answers. But while the NFL tries out $1,500 helmets and neurosurgeons on the ...



Thu, 26 Oct 2017 13:55:25 GMT
227 Marijuana Stocks: Not Even 1 Stock Is Trading Above The 2017 Year-To-Date High - Seeking Alpha

Seeking Alpha

227 Marijuana Stocks: Not Even 1 Stock Is Trading Above The 2017 Year-To-Date High
Seeking Alpha
In the case of the latter, tax loss selling or harvesting and the January effect still occurs, but the market is more efficient and these impacts tend to be statistically significant, but may not be economically significant, and may even be arbitraged ...



Mon, 14 Aug 2017 21:11:15 GMT
Is Marijuana the Answer to the Opioid Epidemic? - Healthline

Is Marijuana the Answer to the Opioid Epidemic?
Healthline
The hope: One day you'll have a choice of varieties or formulations of compounds in marijuana — called “cannabinoids” — that bring relief, aren't addictive, and leave your mind clear. “Cannabinoids will replace opioids for chronic pain in 5 to 10 ...



Tue, 17 May 2016 13:03:00 GMT
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients - GlobeNewswire (press release)

AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
GlobeNewswire (press release)
NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM's proprietary, patent-pending ...
Medical Marijuana, Inc.'s Investment, AXIM Biotech, Launches World's First Cannabigerol (CBG) Clinical Trials on ...Marketwired (press release)

all 6 news articles »